Literature DB >> 7614110

Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: a meta-analysis.

S Eriksson1, G Långström, L Rikner, R Carlsson, J Naesdal.   

Abstract

This paper is a meta-analysis of 30 published, double-blind clinical trials comparing omeprazole with ranitidine or cimetidine for the treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis. These studies compare the recommended doses of omeprazole with those for ranitidine and cimetidine, and the confidence intervals for the therapeutic gain show that the findings are highly reliable. The difference in healing rates favoured omeprazole over ranitidine in patients with duodenal ulcer after 2 weeks of treatment (15.2 percentage units; P < 0.001), and after 4 weeks of treatment in patients with gastric ulcer (9.9 percentage units; P = 0.005), or reflux oesophagitis (23 percentage units; P < 0.001). Similarly, omeprazole gave a 20.6 percentage units higher average healing rate than cimetidine in patients with duodenal ulcer after 2 weeks of treatment (P < 0.0001). Significantly more patients treated with omeprazole were free of symptoms at their first follow-up visit than patients treated with ranitidine or cimetidine.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7614110

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  19 in total

Review 1.  What is potent acid inhibition, and how can it be achieved?

Authors:  Xavier Calvet; Fernando Gomollón
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 2.  Efficacy of rabeprazole once daily for acid-related disorders.

Authors:  F Lanza; K D Bardhan; C Perdomo; R Niecestro; J Barth
Journal:  Dig Dis Sci       Date:  2001-03       Impact factor: 3.199

Review 3.  Optimising acid inhibition treatment.

Authors:  Fernando Gomollón; Xavier Calvet
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Evidence-based clinical practice guidelines for peptic ulcer disease 2015.

Authors:  Kiichi Satoh; Junji Yoshino; Taiji Akamatsu; Toshiyuki Itoh; Mototsugu Kato; Tomoari Kamada; Atsushi Takagi; Toshimi Chiba; Sachiyo Nomura; Yuji Mizokami; Kazunari Murakami; Choitsu Sakamoto; Hideyuki Hiraishi; Masao Ichinose; Naomi Uemura; Hidemi Goto; Takashi Joh; Hiroto Miwa; Kentaro Sugano; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2016-02-15       Impact factor: 7.527

Review 5.  Adverse effects of long-term proton pump inhibitor therapy.

Authors:  Edward Sheen; George Triadafilopoulos
Journal:  Dig Dis Sci       Date:  2011-03-02       Impact factor: 3.199

Review 6.  Proton pump inhibitor-induced hypomagnesaemia and hypocalcaemia: case review.

Authors:  Jonathan Sivakumar
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2016-12-25

7.  Inhibition of lysosomal enzyme activities by proton pump inhibitors.

Authors:  Wensheng Liu; Susan S Baker; Jonathan Trinidad; Alma L Burlingame; Robert D Baker; John G Forte; Lauren P Virtuoso; Nejat K Egilmez; Lixin Zhu
Journal:  J Gastroenterol       Date:  2013-03-12       Impact factor: 7.527

Review 8.  Proton pump inhibitors in cirrhosis: tradition or evidence based practice?

Authors:  Francesca Lodato; Francesco Azzaroli; Maria Di Girolamo; Valentina Feletti; Paolo Cecinato; Andrea Lisotti; Davide Festi; Enrico Roda; Giuseppe Mazzella
Journal:  World J Gastroenterol       Date:  2008-05-21       Impact factor: 5.742

9.  Appropriateness of gastric antisecretory therapy in hospital practice.

Authors:  S S Sebastian; N Kernan; A Qasim; C A O'Morain; M Buckley
Journal:  Ir J Med Sci       Date:  2003 Jul-Sep       Impact factor: 1.568

Review 10.  Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders.

Authors:  P Richardson; C J Hawkey; W A Stack
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.